Details of the Drug
General Information of Drug (ID: DME2PFQ)
Drug Name |
TA-106
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms | FAb antibody fragment (inflammation), Taligen Therapeutics; Anti-factor B FAb (inflammation), Alexion | ||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Antibody
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
ICD Disease Classification | 12 Disease of the respiratory system | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Disease Class | ICD-11: CA23 Asthma | |||||||||||||||||||||||
The Studied Tissue | Nasal and bronchial airway | |||||||||||||||||||||||
The Studied Disease | Asthma [ICD-11:CA23] | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||